Signal mining of adverse reactions for neuraminidase inhibitors in pregnant women: a disproportionality analysis based on the FDA adverse event reporting system database - Summary - MDSpire
Advertisement
Signal mining of adverse reactions for neuraminidase inhibitors in pregnant women: a disproportionality analysis based on the FDA adverse event reporting system database
To analyze adverse events associated with neuraminidase inhibitor (NAI) use in pregnant women using the FDA Adverse Event Reporting System (FAERS) database.
Key Findings:
3,687 adverse drug event reports were retrieved, including 3,211 for oseltamivir and 471 for zanamivir.
Significant adverse events for oseltamivir included proctitis, infantile acne, congenital intestinal obstruction, and placental necrosis.
For zanamivir, significant adverse events included delivery complications, bronchospasm, and pneumothorax.
Interpretation:
Remove unsupported conclusions about the findings supporting the use of neuraminidase inhibitors.
Limitations:
The study relies on the completeness and accuracy of the FAERS database.
Potential underreporting or misclassification of adverse events may affect the results.
Conclusion:
Revise to eliminate unsupported claims regarding safety and clinical decision-making.
